AKRO
Akero Therapeutics, Inc. Healthcare - Biotechnology Investor Relations →
Akero Therapeutics, Inc. (AKRO) closed at $54.65 as of 2025-12-08, trading 62.4% above its 200-week moving average of $33.66. The stock is currently moving closer to the line, down from 62.9% last week. With a 14-week RSI of 80, AKRO is in overbought territory.
Over the past 290 weeks of data, AKRO has crossed below its 200-week moving average 3 times. On average, these episodes lasted 38 weeks. Historically, investors who bought AKRO at the start of these episodes saw an average one-year return of +21.8%.
With a market cap of $4.5 billion, AKRO is a mid-cap stock. Free cash flow yield is currently negative, meaning the company is burning cash. Return on equity stands at -34.5%. The stock trades at 4.6x book value.
Share count has increased 107.4% over three years, indicating dilution.
Over the past 5.7 years, a hypothetical investment of $100 in AKRO would have grown to $215, compared to $242 for the S&P 500. AKRO has returned 14.5% annualized vs 16.9% for the index, underperforming the broader market over this period.
In the past 12 months, corporate insiders have made 1 open-market purchase totaling $8,787,921.
Free cash flow has been declining. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.
Growth of $100: AKRO vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After AKRO Crosses Below the Line?
Across 3 historical episodes, buying AKRO when it crossed below its 200-week moving average produced an average return of +31.5% after 12 months (median +122.0%), compared to +13.5% for the S&P 500 over the same periods. 50% of those episodes were profitable after one year. After 24 months, the average return was +180.5% vs +37.0% for the index.
Each line shows $100 invested at the moment AKRO crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
AKRO has crossed below its 200-week MA 3 times with an average 1-year return of +21.8% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Jun 2021 | Sep 2022 | 63 | 64.6% | -58.9% | +121.1% |
| Oct 2023 | Sep 2024 | 49 | 60.5% | +102.5% | +273.5% |
| Jan 2025 | Jan 2025 | 3 | 11.0% | N/A | +120.0% |
| Average | 38 | — | +21.8% | — |
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of Friday close, 2025-12-08